%	O
%	O
TITLE	O

Molecular	O
and	O
IHC	O
analysis	O
of	O
head	O
and	O
neck	O
carcinomas	O
associated	O
with	O
HPV	O
infection	O
.	O

%	O
%	O
ABSTRACT	O

Head	O
and	O
neck	O
squamous	O
cell	O
carcinomas	O
(	O
HNSCC	O
)	O
are	O
a	O
highly	O
heterogenous	O
disease	O
which	O
can	O
be	O
induced	O
by	O
two	O
main	O
carcinogens	O
-	O
tobacco	O
and	O
/	O
or	O
alcohol	O
,	O
or	O
by	O
HR	O
HPV	O
infection	O
.	O

This	O
work	O
examined	O
60	B-HPV_Sample_Type
paraffin	I-HPV_Sample_Type
-	I-HPV_Sample_Type
embedded	I-HPV_Sample_Type
biopsies	I-HPV_Sample_Type
of	I-HPV_Sample_Type
head	I-HPV_Sample_Type
and	I-HPV_Sample_Type
neck	I-HPV_Sample_Type
carcinomas	I-HPV_Sample_Type
after	O
histological	O
verification	O
.	O

HPV	O
infection	O
,	O
including	O
its	O
specific	O
types	O
in	O
various	O
HNSCC	O
areas	O
,	O
was	O
studied	O
using	O
multiplex	B-HPV_Lab_Technique
qPCR	I-HPV_Lab_Technique
.	I-HPV_Lab_Technique

Expression	O
levels	O
of	O
p16INK4A	O
and	O
p53	O
were	O
detected	O
by	O
subsequent	O
IHC	O
analysis	O
as	O
being	O
potential	O
diagnostic	O
markers	O
.	O

Based	O
on	O
the	O
assumption	O
that	O
patients	B-Study_Cohort
with	I-Study_Cohort
HNSCC	I-Study_Cohort
could	O
benefit	O
from	O
anti	O
-	O
EGFR	O
therapy	O
(	O
cetuximab	O
)	O
,	O
but	O
the	O
predictors	O
are	O
not	O
yet	O
defined	O
,	O
analyses	B-HPV_Lab_Technique
of	I-HPV_Lab_Technique
point	I-HPV_Lab_Technique
mutations	I-HPV_Lab_Technique
of	I-HPV_Lab_Technique
ras	I-HPV_Lab_Technique
genes	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
Kras	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
Nras	I-HPV_Lab_Technique
)	I-HPV_Lab_Technique
were	I-HPV_Lab_Technique
carried	I-HPV_Lab_Technique
out	I-HPV_Lab_Technique
using	I-HPV_Lab_Technique
multiplex	I-HPV_Lab_Technique
qPCR	I-HPV_Lab_Technique
and	I-HPV_Lab_Technique
sequence	I-HPV_Lab_Technique
analysis	I-HPV_Lab_Technique
of	I-HPV_Lab_Technique
the	I-HPV_Lab_Technique
Braf	I-HPV_Lab_Technique
gene	I-HPV_Lab_Technique
.	O

All	O
statistical	O
data	O
were	O
processed	O
by	O
ChÃ­	O
-	O
x2	O
test	O
.	O
HPV	O
infection	O
was	O
detected	O
in	O
23	O
.	O
34	O
%	O
of	O
cases	O
with	O
HNSCC	O
,	O
of	O
which	O
100	O
%	O
were	O
HPV	O
16	O
,	O
which	O
is	O
the	O
most	O
frequently	O
infection	O
found	O
in	O
the	O
oropharyngeal	O
region	O
.	O

Using	B-HPV_Lab_Technique
IHC	I-HPV_Lab_Technique
analysis	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
a	I-HPV_Lab_Technique
positive	I-HPV_Lab_Technique
expression	I-HPV_Lab_Technique
of	I-HPV_Lab_Technique
P16INK4A	I-HPV_Lab_Technique
was	I-HPV_Lab_Technique
detected	I-HPV_Lab_Technique
in	O
100	O
%	O
of	O
HPV	O
-	O
positive	O
HNSCC	O
while	O
this	O
expression	O
was	O
discovered	O
to	O
be	O
highly	O
correlated	O
with	O
HPV	O
infection	O
.	O

Furthermore	O
,	O
a	O
correlation	O
between	O
p53	O
and	O
HPV	O
-	O
negative	O
HNSCC	O
was	O
proved	O
.	O

The	O
mutation	O
incidence	O
was	O
the	O
highest	O
in	O
the	O
Kras	O
gene	O
(	O
codon	O
12	O
and	O
codon	O
146	O
)	O
,	O
Nras	O
(	O
codon	O
12	O
)	O
and	O
Braf	O
.	O

A	O
correlation	O
between	O
tumor	O
location	O
in	O
the	O
oropharyngeal	O
region	O
and	O
Kras	O
mutations	O
was	O
proved	O
.	O

The	O
HPV	O
infection	O
correlated	O
with	O
Kras	O
mutations	O
in	O
case	O
of	O
codon	O
146	O
but	O
on	O
the	O
grounds	O
of	O
low	O
amount	O
of	O
output	O
data	O
,	O
these	O
figures	O
could	O
be	O
irrelevant	O
.	O

In	O
one	O
case	O
,	O
c	O
.	O
1808	O
G	O
>	O
A	O
,	O
protein	O
603	O
Arg	O
>	O
Gln	O
mutation	O
was	O
found	O
in	O
the	O
Braf	O
gene	O
but	O
its	O
correlation	O
with	O
head	O
and	O
neck	O
carcinomas	O
has	O
not	O
been	O
described	O
yet	O
(	O
Tab	O
.	O

2	O
,	O
Fig	O
.	O

2	O
,	O
Ref	O
.	O

24	O
)	O
.	O

Keywords	O
:	O
head	O
and	O
neck	O
carcinomas	O
,	O
biopsy	O
,	O
HPV	O
types	O
,	O
PCR	B-HPV_Lab_Technique
,	O
p16INK4A	O
,	O
p53	O
,	O
molecular	O
predictors	O
,	O
Kras	O
,	O
Nras	O
,	O
Braf	O
.	O

%	O
%	O
MATERIALS	O
AND	O
METHODS	O

The	O
aim	O
of	O
this	O
work	O
was	O
to	O
study	O
HPV	O
infection	O
in	O
various	O
areas	O
of	O
head	O
and	O
neck	O
carcinomas	O
using	O
retrospective	B-Study_Type
analysis	I-Study_Type
,	I-Study_Type
compare	O
the	O
incidence	B-Incidence_or_Prevalence
and	O
frequency	O
of	O
HPV	O
types	O
,	O
determine	O
the	O
expression	O
of	O
p16INK4A	O
protein	O
and	O
p53	O
protein	O
,	O
and	O
find	O
their	O
possible	O
correlation	O
with	O
HPV	O
infection	O
,	O
as	O
well	O
as	O
on	O
the	O

Bratisl	O
Med	O
J	O
2019	O
;	O
120	O
(	O
11	O
)	O

832	O
–	O
838	O

basis	O
of	O
these	O
data	O
to	O
suggest	O
their	O
pos	O
-	O
sible	O
use	O
as	O
potential	O
diagnostic	O
biomark	O
-	O
ers	O
.	O

Mutations	O
of	O
the	O
RAS	O
gene	O
family	O
are	O
tested	O
,	O
specifically	O
those	O
of	O
Kras	O
and	O
Nras	O
in	O
exon	O
2	O
,	O
3	O
and	O
4	O
,	O
and	O
Braf	O
gene	O
,	O
to	O
study	O
the	O
correlation	O
of	O
these	O
genes’	O
mutations	O
with	O
risk	O
factors	O
and	O
HPV	O
infection	O
and	O
their	O
possible	O
role	O
of	O
potential	O
predictors	O
of	O
cetuximab	O
-	O
targeted	O
therapy	O
.	O

The	B-Study_Cohort
overall	I-Study_Cohort
cohort	I-Study_Cohort
consisted	I-Study_Cohort
of	I-Study_Cohort
60	I-Study_Cohort
pa	I-Study_Cohort
-	I-Study_Cohort
tients	I-Study_Cohort
with	I-Study_Cohort
histologically	I-Study_Cohort
confirmed	I-Study_Cohort
head	I-Study_Cohort
and	I-Study_Cohort
neck	I-Study_Cohort
carcinomas	I-Study_Cohort
.	O

There	O
were	O
tumors	O
of	O
the	O
oral	O
cavity	O
(	O
oral	O
-	O
dental	O
socket	O
,	O
hard	O
palate	O
,	O
buccal	O
area	O
and	O
tongue	O
,	O
tumors	O
of	O
the	O
oropharynx	O
(	O
OP	O
–	O
oropharyngeal	O
)	O
and	O
tumors	O
of	O
the	O
larynx	O
(	O
non	O
-	O
OP	O
–	O
non	O
-	O
oro	O
-	O
pharyngeal	O
)	O
.	O

The	O
group	O
of	O
patients	O
aged	O
between	O
29	B-Minimum_Age_in_Study_Cohort
and	O
96	B-Maximum_Age_in_Study_Cohort
consisted	O
of	O
48	O
men	O

(	O
80	O
%	O
)	O
–	O
median	O
age	O
64	O
.	O
89	O
years	O
and	O
12	O
women	O
(	O
20	O
%	O
)	O
–	O
median	O
age	O
59	O
.	O
16	O
years	O
.	O

Fig	O
.	O

1	O
.	O

A	O
)	O
HPV	O
-	O
positive	O
p16INK4A	O
-	O
positive	O
cell	O
carcinoma	O
squamous	O
cell	O
.	O

B	O
)	O
HPV	O
-	O
negative	O
squamous	O
cell	O
carcinoma	O
with	O
negative	O
p16INK4A	O
.	O

C	O
)	O
HPV	O
-	O
negative	O
p53	O
carcinoma	O
-	O
positive	O
cell	O
carcinoma	O
.	O

D	O
)	O
HPV	O
-	O
positive	O
p53	O
-	O
negative	O
carcinoma	O
cell	O
(	O
yellow	O
arrow	O
)	O
.	O

Eight	O
patients	O
already	O
died	O
.	O

Thirty	O
-	O
two	O
patients	O
(	O
out	O
of	O
60	O
;	O
53	O
.	O
4	O
%	O
)	O
used	O
tobacco	O
in	O
the	O
past	O
.	O

The	O
percentage	O
of	O
patients	O
who	O
consumed	O
alcohol	O
in	O
the	O
past	O
could	O
not	O
be	O
defined	O
as	O
this	O
is	O
a	O
retrospective	B-Study_Type
study	I-Study_Type
and	O
patients	O
were	O
not	O
chosen	O
on	O
the	O
basis	O
of	O
a	O
questionnaire	O
.	O

Histologically	O
,	O
the	O
tumors	O
were	O
squamous	O
cell	O
carcinomas	O
.	O

In	O
all	O
patients	O
,	O
the	O
tissue	B-HPV_Sample_Type
was	O
taken	O
for	O
analysis	O
from	O
the	O
primary	O
tumor	O
site	O
,	O
including	O
resection	O
margins	O
.	O

As	O
many	O
as	O
4‒6	O
tissue	B-HPV_Sample_Type
sections	O
were	O
used	O
for	O
isolation	O
af	O
-	O
ter	O
previous	O
deparaffinization	O
using	O
QIAamp®	O
DNA	O
Mini	O
Kit	O
(	O
250	O
)	O
;	O
Dynex	O
.	O

HPV	B-HPV_Lab_Technique
analysis	I-HPV_Lab_Technique
was	I-HPV_Lab_Technique
carried	I-HPV_Lab_Technique
out	I-HPV_Lab_Technique
using	I-HPV_Lab_Technique
quantitative	I-HPV_Lab_Technique
multiplex	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
in	I-HPV_Lab_Technique
real	I-HPV_Lab_Technique
time	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
Real	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
Time	I-HPV_Lab_Technique
High	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
Risk	I-HPV_Lab_Technique
HPV	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
96	I-HPV_Lab_Technique
)	I-HPV_Lab_Technique
;	I-HPV_Lab_Technique
KitGen	I-HPV_Lab_Technique
in	I-HPV_Lab_Technique
RotorGene	I-HPV_Lab_Technique
Q	I-HPV_Lab_Technique
;	I-HPV_Lab_Technique
Dynex	I-HPV_Lab_Technique
.	O

The	O
reaction	O
is	O
based	O
on	O
the	O
system	O
of	O
pathogen	O
-	O
specific	O
primers	O
and	O
probes	O
that	O
recognize	O
their	O
specific	O
target	O
during	O
quantitative	O
Real	B-HPV_Lab_Technique
-	I-HPV_Lab_Technique
Time	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
(	O
Tab	O
.	O

1	O
)	O
.	O

The	O
internal	O
control	O
(	O
IC	O
)	O
detects	O
authentic	O
human	O
genes	O
.	O

To	O
maintain	O
the	O
maxi	O
-	O
mal	O
sensitivity	O
of	O
the	O
diagnostic	O
set	O
,	O
the	O
internal	O
control	O
is	O
ampli	O
-	O
fied	O
in	O
a	O
separate	O
test	O
tube	O
.	O

IHC	B-HPV_Lab_Technique
was	I-HPV_Lab_Technique
carried	I-HPV_Lab_Technique
out	I-HPV_Lab_Technique
on	I-HPV_Lab_Technique
paraffin	I-HPV_Lab_Technique
tissue	I-HPV_Lab_Technique
sections	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
3‒4	I-HPV_Lab_Technique
μm	I-HPV_Lab_Technique
wide	I-HPV_Lab_Technique
.	I-HPV_Lab_Technique

P16	I-HPV_Lab_Technique
detection	I-HPV_Lab_Technique
was	I-HPV_Lab_Technique
performed	I-HPV_Lab_Technique
using	I-HPV_Lab_Technique
mouse	I-HPV_Lab_Technique
monoclonal	I-HPV_Lab_Technique
antibody	I-HPV_Lab_Technique
supplied	I-HPV_Lab_Technique
by	I-HPV_Lab_Technique
GenomeME	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
clone	O
IHC016	O
.	O

P53	O
detection	O
was	O
per	O
-	O
formed	O
using	O
the	O
antibody	O
supplied	O
by	O
Roche	O
,	O
clone	O
DO	O
-	O
7	O
.	O

In	O
both	O
cases	O
,	O
the	O
data	O
were	O
robotically	O
analyzed	O
on	O
BenchMark	O
ULTRA	O
(	O
Ventana	O
Medical	O
Systems	O
;	O
Roche	O
)	O
.	O

For	O
detecting	O
the	O
somatic	O
point	O
mutations	O
of	O
Kras	O
and	O
Nras	O
gene	O
codons	O
12	O
/	O
13	O
in	O
exon	O
2	O
,	O
codon	O
61	O
in	O
exon	O
3	O
and	O
codon	O
146	O
in	O
exon	O
4	O
,	O
the	O
kit	O
QClamp™	O
KRAS	O
and	O
NRAS	O
Codon	O
Specific	O
Mutation	O
Detection	O
Kit	O
;	O
DiaCarta	O
on	O
LightCycler	O
480	O
II	O
,	O
Roche	O
were	O
used	O
.	O

Tab	O
.	O

1	O
.	O

The	O
system	O
of	O
pathogen	O
-	O
specific	O
primers	O
and	O
probes	O
that	O
re	O
-	O
cognize	O
their	O
specific	O
target	O
during	O
quantitative	O
Real	B-HPV_Lab_Technique
-	I-HPV_Lab_Technique
Time	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
.	O

Reverse	O
primer	O
5´CTGTTCAAACTGATGGGACCC	O
3´	O
Forward	O
primer	O
5´TGCTTGCTCTGATAGGAAAATG	O
3´	O

Sanger	O
sequencing	O
was	O
used	O
for	O
detecting	O
mutations	O
in	O
exon	O
15	O
of	O
the	O
Braf	O
gene	O
.	O

Primers	O
were	O
proposed	O
on	O
the	O
basis	O
of	O
Gen	O
-	O
Ban	O
sequences	O
using	O
Primer	O
3	O
software	O
,	O
including	O
intron	O
-	O
exon	O
boundaries	O
(	O
Tab	O
.	O

1	O
)	O
.	O

PCR	O
products	O
were	O
purified	O
and	O
sequenced	O
using	O
BigDye	O
Terminator	O
v	O
.	O
3	O
.	O

1	O
Cycle	O
Sequencing	O
Kit	O
(	O
Applied	O
Biosystems	O
)	O
on	O
ABI	O
Prism	O
3130	O
Avant	O
Genetic	O
Analyzer	O
.	O

Chí	O
-	O
x2	O
test	O
was	O
used	O
for	O
statistical	O
evaluation	O
of	O
HPV	O
,	O
p16	O
,	O
p53	O
and	O
Kras	O
,	O
Nras	O
and	O
Braf	O
mutations	O
.	O

Software	O
Excel	O
,	O
Micro	O
-	O
soft®	O
was	O
used	O
for	O
statistical	O
analysis	O
.	O

Variables	O
with	O
p	O
<	O
0	O
.	O
05	O
were	O
considered	O
statistically	O
significant	O
.	O

Results	O
and	O
discussion	O

HPV	O
genome	O
was	O
detected	O
in	O
14	O
/	O
60	O
(	O
23	O
.	O
34	O
%	O
)	O
patients	O
and	O
HPV	O
type	O
16	O
was	O
identified	O
in	O
14	O
/	O
14	O
(	O
100	O
%	O
)	O
cases	O
.	O

The	O
detection	O
of	O
HPV	O
positivity	O
varied	O
in	O
particular	O
locations	O
of	O
HNSCC	O
.	O

There	O
was	O
a	O
difference	O
in	O
HPV	O
prevalence	B-Incidence_or_Prevalence
between	O
oral	O
,	O
OP	O
and	O
non	O
-	O
OP	O
carcinomas	O
.	O

As	O
many	O
as	O
5	O
/	O
40	O
oral	O
carcinomas	O
were	O
HPV	O
-	O
positive	O
,	O
6	O
/	O
10	O
OP	O
carcinomas	O
were	O
HPV	O
-	O
positive	O
,	O
and	O
3	O
/	O
10	O
non	O
-	O
OP	O
carcino	O
-	O
mas	O
were	O
HPV	O
-	O
positive	O
The	O
correlation	O
between	O
cancer	O
location	O
and	O
HPV	O
status	O
was	O
detected	O
only	O
in	O
case	O
of	O
the	O
oropharynx	O
(	O
p	O
=	O
0	O
.	O
006	O
)	O
and	O
tongue	O
(	O
p	O
=	O
0	O
.	O
052	O
)	O
while	O
only	O
marginal	O
interactions	O
were	O
found	O
in	O
other	O
HNSCC	O
locations	O
.	O

More	O
HPV	O
-	O
positive	O
HNSCC	O
were	O
found	O
in	O
males	O
(	O
85	O
.	O
7	O
%	O
)	O
than	O
in	O
females	O
(	O
14	O
.	O
3	O
%	O
)	O
,	O
thus	O
the	O
correlation	O
with	O
gender	O
was	O
shown	O
to	O
be	O
strong	O
(	O
p	O
=	O
0	O
.	O
003	O
)	O
.	O

In	O
HPV	O
-	O
negative	O
tumors	O
,	O
no	O
cor	O
-	O
relation	O
with	O
gender	O
was	O
detected	O
(	O
p	O
=	O
0	O
.	O
768	O
)	O
.	O

The	O
age	O
in	O
male	O
patients	O
did	O
not	O
play	O
any	O
role	O
in	O
HPV	O
-	O
positive	O
tumor	O
location	O
(	O
p	O
=	O
0	O
.	O
720	O
)	O
(	O
Figs	O
1	O
and	O
2	O
)	O
.	O

The	O
correlation	O
between	O
age	O
and	O
HPV	O
-	O
positive	O
tumors	O
was	O
marginal	O
in	O
both	O
genders	O
(	O
p	O
=	O
0	O
.	O
065	O
)	O
.	O

The	O
location	O
of	O
HPV	O
-	O
positive	O
tumors	O
did	O
not	O
correlate	O
with	O
age	O
(	O
p	O
=	O
0	O
.	O
405	O
)	O
.	O

A	O
positive	O
p16	O
expression	O
was	O
detected	O
in	O
17	O
/	O
60	O
(	O
28	O
.	O
33	O
%	O
)	O
cases	O
of	O
HNSCC	O
.	O

Thep16INK4A	O
expression	O
was	O
not	O
detected	O
in	O
43	O
/	O
60	O
(	O
71	O
.	O
67	O
%	O
)	O
cases	O
,	O
and	O
in	O
2	O
/	O
43	O
(	O
4	O
.	O
65	O
%	O
)	O
cases	O
,	O
it	O
was	O
not	O

Stanek	O
L	O
et	O
al	O
.	O

Molecular	O
and	O
IHC	B-HPV_Lab_Technique
analysis	O
of	O
head	O
and	O
neck	O
carcinomas	O
associated	O
with	O
HPV	O
infection	O

Fig	O
.	O

2	O
Sequence	O
from	O
mutation	O
analysis	O
of	O
c	O
.	O
1808	O
G	O
>	O
A	O
,	O
protein	O
603	O
Arg	O
>	O
Gln	O
.	O

possible	O
to	O
specify	O
p16INK4A	O
expression	O
.	O

The	O
latter	O
cases	O
were	O
thus	O
regarded	O
as	O
negative	O
.	O

The	O
p16INK4A	O
expression	O
was	O
detected	O
in	O
14	O
/	O
14	O
HPV	O
-	O
positive	O
samples	B-HPV_Sample_Type
(	O
100	O
%	O
)	O
and	O
in	O
3	O
/	O
46	O
HPV	O
-	O
negative	O
samples	B-HPV_Sample_Type
(	O
6	O
.	O
52	O
%	O
)	O
.	O

The	O
correlation	O
between	O
the	O
positive	O
expression	O
of	O
p16INK4A	O
and	O
HPV	O
status	O
was	O
found	O
to	O
be	O
strong	O
(	O
p	O
≤	O
0	O
.	O
001	O
)	O
.	O

The	O
correlation	O
between	O
p16INK4A	O
expression	O
and	O
gender	O
/	O
age	O
imitates	O
the	O
HPV	O
incidence	B-Incidence_or_Prevalence
.	O

The	O
p53	O
expression	O
was	O
detected	O
as	O
positive	O
in	O
25	O
/	O
60	O
(	O
41	O
.	O
7	O
%	O
)	O
cases	O
of	O
HNSCC	O
.	O

The	O
p53	O
expression	O
was	O
not	O
detected	O
in	O
35	O
/	O
60	O
(	O
58	O
.	O
3	O
%	O
)	O
cases	O
,	O
while	O
in	O
5	O
/	O
35	O
(	O
14	O
.	O
3	O
%	O
)	O
cases	O
,	O
it	O
could	O
not	O
be	O
iden	O
-	O
tified	O
.	O

The	O
latter	O
cases	O
were	O
thus	O
regarded	O
as	O
negative	O
.	O

The	O
p53	O
expression	O
was	O
detected	O
in	O
2	O
/	O
14	O
HPV	O
-	O
positive	O
samples	B-HPV_Sample_Type
(	O
14	O
.	O
3	O
%	O
)	O
and	O
in	O
23	O
/	O
46	O
HPV	O
-	O
negative	O
samples	B-HPV_Sample_Type
(	O
50	O
%	O
)	O
.	O

A	O
simulta	O
-	O
neously	O
positive	O
expression	O
of	O
p16	O
protein	O
and	O
p53	O
protein	O
was	O
found	O
in	O
2	O
HPV	O
-	O
positive	O
tumors	O
and	O
in	O
one	O
HPV	O
-	O
negative	O
tumor	O
.	O

A	O
marginal	O
correlation	O
between	O
positive	O
expression	O
of	O
p53	O
and	O
HPV	O
-	O
negative	O
tumors	O
was	O
found	O
(	O
p	O
=	O
0	O
.	O
069	O
)	O
.	O

The	O
interac	O
-	O
tion	O
between	O
location	O
of	O
HPV	O
-	O
negative	O
tumors	O
and	O
positive	O
p53	O
expression	O
was	O
found	O
only	O
in	O
cases	O
with	O
affliction	O
of	O
hard	O
palate	O
(	O
p	O
=	O
0	O
.	O
042	O
)	O
and	O
buccal	O
area	O
(	O
p	O
=	O
0	O
.	O
049	O
)	O
.	O

The	O
correlation	O
between	O
age	O
and	O
positive	O
p53	O
expression	O
was	O
not	O
found	O
(	O
p	O
=	O
0	O
.	O
328	O
)	O
as	O
well	O
as	O
the	O
correlation	O
between	O
p53	O
expression	O
and	O
gender	O
(	O
p	O
=	O
0	O
.	O
317	O
)	O

and	O
smoking	O
(	O
p	O
=	O
0	O
.	O
590	O
)	O
(	O
Tab	O
.	O

2	O
)	O
.	O

The	O
mutation	O
analysis	O
of	O
the	O
Kras	O
gene	O
-	O
5	O
/	O
60	O
cases	O
is	O
not	O
included	O
into	O
the	O
study	O
results	O
on	O
the	O
grounds	O
of	O
invalid	O
results	O
of	O
real	B-HPV_Lab_Technique
-	I-HPV_Lab_Technique
time	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
.	O

On	O
that	O
account	O
,	O
the	O
overall	O
cohort	O
consists	O
of	O
55	O
patients	O
.	O

The	O
Kras	O
mutation	O
was	O
detected	O
in	O
7	O
/	O
55	O
tumors	O
(	O
12	O
.	O
72	O
%	O
)	O
.	O

As	O
many	O
as	O
48	O
/	O
55	O
tumors	O
(	O
87	O
.	O
28	O
%	O
)	O
were	O
detected	O
as	O
wild	O
type	O
.	O

Mutations	O
were	O
found	O
in	O
two	O
codons	O
,	O
namely	O
in	O
codon	O
12	O
exon	O
2	O
and	O
codon	O
146	O
exon	O
4	O
.	O

Mutations	O
in	O
codon	O
12	O
were	O
present	O
in	O
5	O
/	O
7	O
tumors	O
(	O
71	O
.	O
42	O
%	O
)	O
while	O
those	O
in	O
codon	O
146	O
were	O
in	O
2	O
/	O
7	O
tu	O
-	O
mors	O
(	O
28	O
.	O
58	O
%	O
)	O
.	O

Age	O
and	O
gender	O
were	O
not	O
related	O
to	O
mutations	O
in	O
codon	O
12	O
(	O
p	O
=	O
0	O
.	O
263	O
;	O
p	O
=	O
0	O
.	O
525	O
)	O
and	O
mutations	O
in	O
codon	O
146	O
(	O
p	O
=	O
0	O
.	O
479	O
;	O
p	O

=	O
0	O
.	O
487	O
)	O
.	O

The	O
correlation	O
between	O
tumor	O
locations	O
and	O
codon	O
12	O
muta	O
-	O
tions	O
was	O
found	O
only	O
in	O
case	O
of	O
oropharynx	O
affliction	O
(	O
p	O
≤	O
0	O
.	O
011	O
)	O
.	O

The	O
correlation	O
between	O
mutations	O
and	O
oropharyngeal	O
tumors	O
was	O
found	O
also	O
in	O
codon	O
146	O
(	O
p	O
≤	O
0	O
.	O
003	O
)	O
.	O

Regarding	O
HPV	O
status	O
,	O
the	O
codon	O
12	O
mutation	O
was	O
found	O
only	O
in	O
one	O
HPV	O
-	O
positive	O
tumor	O
(	O
p	O
=	O
0	O
.	O
779	O
)	O
.	O

The	O
codon	O
146	O
mutation	O
was	O
found	O
in	O
two	O
HPV	O
-	O
positive	O
tumors	O
(	O
p	O
=	O
0	O
.	O
041	O
)	O
,	O
thus	O
HPV	O
-	O
positive	O
tumors	O
and	O
codon	O
146	O
mutations	O
correlate	O
.	O

Kras	O
mutations	O
(	O
codon	O
12	O
and	O
codon	O
146	O
)	O
strongly	O
correlated	O
with	O
smoking	O
(	O
p	O
≤	O
0	O
.	O
001	O
)	O
.	O

The	O
mutation	O
analysis	O
of	O
the	O
Nras	O
gene	O
(	O
6	O
/	O
60	O
cases	O
)	O
is	O
not	O
included	O
into	O
the	O
study	O
results	O
on	O
the	O
grounds	O
of	O
invalid	O
results	O
of	O
real	B-HPV_Lab_Technique
-	I-HPV_Lab_Technique
time	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
.	O

On	O
that	O
account	O
,	O
the	O
overall	O
cohort	O
consists	O
of	O
54	O
cases	O
.	O

Nras	O
mutations	O
in	O
exon	O
2	O
were	O
detected	O
in	O
2	O
/	O
54	O
tumors	O
(	O
3	O
.	O
7	O
%	O
)	O
.	O

Nras	O
was	O
detected	O
as	O
a	O
wild	O
type	O
(	O
wt	O
)	O
in	O
52	O
/	O
54	O
tumors	O
(	O
96	O
.	O
3	O
%	O
)	O
Mutations	O
were	O
detected	O
only	O
in	O
codon	O
12	O
.	O

No	O
interactions	O
between	O
codon	O
12	O
mutation	O
and	O
gender	O
(	O
p	O
=	O
0	O
.	O
298	O
)	O
and	O
codon	O
12	O
mutation	O
and	O
age	O
(	O
p	O
=	O
0	O
.	O
476	O
)	O
were	O
found	O
.	O

The	O
codon	O
12	O
mutation	O
was	O
detected	O
only	O
in	O
one	O
HPV	O
-	O
positive	O
tumor	O
(	O
p	O
=	O
0	O
.	O
437	O
)	O
.	O

Smoking	O
did	O
not	O
correlate	O
with	O
Nras	O
mutations	O
.	O

Statistically	O
,	O
no	O
correlation	O
between	O
Nras	O
and	O
Kras	O
mutations	O
and	O
HPV	O
infection	O
was	O
found	O
(	O
p	O
=	O
0	O
.	O
190	O
)	O
.	O

Mutation	O
analysis	O
of	O
the	O
Braf	O
gene	O
(	O
6	O
/	O
60	O
cases	O
)	O
are	O
not	O
in	O
-	O
cluded	O
into	O
the	O
study	O
results	O
on	O
the	O
grounds	O
of	O
invalid	O
results	O
of	O
real	B-HPV_Lab_Technique
-	I-HPV_Lab_Technique
time	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
.	O

On	O
that	O
account	O
,	O
the	O
overall	O
cohort	O
consists	O
of	O
54	O
patients	O
.	O

The	O
Braf	O
gene	O
mutation	O
(	O
c	O
.	O
1808	O
G	O
>	O
A	O
)	O
was	O
detected	O
in	O
one	O
tumor	O
(	O
1	O
.	O
85	O
%	O
)	O
.	O

Tab	O
.	O

2	O
.	O

The	O
correlation	O
between	O
age	O
and	O
positive	O
p53	O
expression	O
and	O
the	O
correlation	O
between	O
p53	O
expression	O
and	O
gender	O
and	O
smoking	O
.	O

Bratisl	O
Med	O
J	O
2019	O
;	O
120	O
(	O
11	O
)	O

832	O
–	O
838	O

Gender	O
and	O
age	O
did	O
not	O
correlate	O
with	O
Braf	O
mutations	O
(	O
p	O
=	O
0	O
.	O
613	O
and	O
p	O
=	O
0	O
.	O
082	O
,	O
respectively	O
)	O
.	O

Regarding	O
location	O
,	O
a	O
mar	O
-	O
ginal	O
correlation	O
was	O
found	O
only	O
in	O
case	O
of	O
larynx	O
affliction	O
(	O
p	O

=	O
0	O
.	O
054	O
)	O
.	O

The	O
Braf	O
mutation	O
was	O
detected	O
in	O
one	O
HPV	O
-	O
positive	O
tumor	O
(	O
p	O
≤	O
0	O
.	O
001	O
)	O
.	O

Smoking	O
was	O
not	O
associated	O
with	O
Braf	O
muta	O
-	O
tions	O
(	O
p	O
=	O
0	O
.	O
335	O
)	O
.	O

The	O
head	O
and	O
neck	O
carcinomas	O
are	O
the	O
fourth	O
most	O
frequent	O
malignancies	O
in	O
men	O
from	O
European	B-Study_Location
countries	O
.	O

Papillomaviruses	O
increase	O
the	O
risk	O
of	O
HNSCC	O
by	O
changing	O
the	O
molecular	O
profile	O
of	O
patients	O
.	O

HPV	O
infection	O
is	O
causally	O
associated	O
with	O
HNSCC	O
in	O
-	O
dependently	O
of	O
two	O
major	O
etiologic	O
factors	O
,	O
tobacco	O
and	O
alcohol	O
.	O

In	O
this	O
study	O
we	O
evaluated	O
the	O
prevalence	B-Incidence_or_Prevalence
of	O
HPV	O
infection	O
as	O
well	O
as	O
analyzed	O
HPV	O
types	O
in	O
60	O
patients	O
with	O
HNSCC	O
.	O

HPV	O
infection	O
was	O
detected	O
in	O
14	O
patients	O
and	O
solely	O
HPV	O
type	O
16	O
infection	O
was	O
identified	O
.	O

This	O
type	O
is	O
frequently	O
detected	O
in	O
HN	O
-	O
SCC	O
and	O
is	O
also	O
the	O
most	O
frequent	O
type	O
causing	O
cervical	O
cancer	O
in	O
women	O
(	O
11	O
,	O
12	O
)	O
.	O

Differences	O
were	O
found	O
in	O
HPV	O
infection	O
incidence	O
according	O
to	O
the	O
location	O
.	O

The	O
most	O
of	O
HPV	O
-	O
positive	O
tumors	O
were	O
found	O
in	O
the	O
oropharyngeal	O
area	O
where	O
HPV	O
-	O
positive	O
tumors	O
represented	O

42	O
.	O
8	O
%	O
of	O
all	O
cases	O
.	O

The	O
incidence	O
in	O
other	O
studied	O
areas	O
was	O
low	O
-	O
er	O
(	O
oral	O
tumors	O
‒	O
35	O
.	O
7	O
%	O
,	O
non	O
-	O
oropharyngeal	O
tumors	O
‒	O
21	O
.	O
5	O
%	O
)	O
.	O

Our	O
results	O
parallel	O
the	O
observations	O
of	O
previous	O
studies	O
of	O
Kreimer	O
et	O
al	O
and	O
Faust	O
et	O
al	O
,	O
the	O
results	O
of	O
whom	O
confirm	O
that	O
the	O
most	O
frequent	O
location	O
of	O
HPV	O
infection	O
was	O
in	O
the	O
oropharynx	O
,	O
followed	O
by	O
oral	O
cavity	O
and	O
larynx	O
(	O
13	O
,	O
14	O
)	O
.	O

HPV	O
infection	O
,	O
especially	O
he	O
high	O
-	O
risk	O
types	O
play	O
an	O
im	O
-	O
portant	O
role	O
in	O
the	O
molecular	O
mechanisms	O
of	O
carcinogenesis	O
by	O
means	O
of	O
viral	O
oncoproteins	O
E6	O
and	O
E7	O
.	O

E6	O
binds	O
to	O
p53	O
and	O
de	O
-	O
termines	O
it	O
to	O
proteasome	O
-	O
dependent	O
degradation	O
whereas	O
E7	O
binds	O
and	O
inactivates	O
pRb	O
tumor	O
suppressor	O
,	O
which	O
leads	O
to	O
ex	O
-	O
cessive	O
p16	O
expression	O
via	O
the	O
loss	O
of	O
negative	O
feedback	O
.	O

P16	O
and	O
p53	O
are	O
tumor	O
suppressor	O
genes	O
and	O
key	O
targets	O
in	O
the	O
loss	O
of	O
cell	O
cycle	O
control	O
.	O

In	O
this	O
study	O
,	O
similarly	O
to	O
that	O
conducted	O
by	O
Wittekindt	O
et	O
al	O
,	O
the	O
p16	O
expression	O
was	O
observed	O
in	O
all	O
HPV	O
-	O
positive	O
HNSCC	O
(	O
15	O
)	O
.	O

Wittekindt	O
studied	O
the	O
correlation	O
between	O
HPV	O
-	O
positive	O
and	O
p16	O
-	O
positive	O
HNSCC	O
and	O
found	O
p16	O
expression	O
to	O
be	O
present	O
in	O
all	O
HPV	O
-	O
positive	O
neoplastic	O
cells	O
.	O

The	O
p16	O
immunoreactivity	O
probably	O
starts	O
from	O
transcrip	O
-	O
tionally	O
active	O
HPV	O
infection	O
which	O
is	O
supported	O
by	O
the	O
fact	O
that	O
HPV	O
-	O
positive	O
HNSCC	O
makes	O
up	O
a	O
biologically	O
different	O
tumor	O
entity	O
.	O

The	O
p16	O
immunohistochemical	O
staining	O
of	O
HNSCC	O
can	O
be	O
used	O
as	O
a	O
reliable	O
diagnostic	O
biomarker	O
of	O
HPV	O
-	O
positive	O
HNSCC	O
as	O
well	O
as	O
in	O
routine	O
diagnostic	O
histopathology	O
.	O

In	O
HPV	O
-	O
negative	O
head	O
and	O
neck	O
carcinomas	O
,	O
the	O
tumor	O
sup	O
-	O
pressor	O
gene	O
p53	O
is	O
frequently	O
mutated	O
(	O
16	O
)	O
.	O

In	O
HPV	O
-	O
positive	O
HN	O
-	O
SCC	O
,	O
TP53	O
mutations	O
are	O
less	O
probable	O
because	O
the	O
protein	O
p53	O
is	O
inactivated	O
rather	O
than	O
mutated	O
,	O
or	O
overexpressed	O
by	O
means	O
of	O
HPV	O
E6	O
protein	O
(	O
5	O
)	O
.	O

In	O
this	O
study	O
,	O
a	O
positive	O
expression	O
of	O
p53	O
was	O
detected	O
in	O

38	O
.	O
4	O
%	O
of	O
HPV	O
-	O
negative	O
tumors	O
and	O
only	O
in	O
3	O
.	O
3	O
%	O
of	O
HPV	O
-	O
posi	O
-	O
tive	O
HNSCC	O
.	O

Risk	O
factors	O
such	O
as	O
age	O
and	O
gender	O
did	O
not	O
play	O
any	O
role	O
in	O
positive	O
expression	O
of	O
p53	O
.	O

Regarding	O
the	O
location	O
,	O
an	O
as	O
-	O
sociation	O
of	O
non	O
-	O
HPV	O
and	O
positive	O
expression	O
of	O
p53	O
was	O
found	O

in	O
the	O
hard	O
palate	O
and	O
buccal	O
areas	O
.	O

Nevertheless	O
,	O
no	O
bibliography	O
is	O
available	O
to	O
compare	O
these	O
data	O
.	O

In	O
the	O
older	O
study	O
of	O
Nadal	O
et	O
al	O
,	O
the	O
HPV	O
status	O
in	O
HNSCC	O
was	O
not	O
taken	O
into	O
consideration	O
.	O

The	O
study	O
only	O
demonstrated	O
that	O
the	O
p53	O
expression	O
can	O
be	O
the	O
initial	O
genetic	O
change	O
in	O
the	O
development	O
of	O
squamous	O
cell	O
carcinomas	O
(	O
17	O
)	O
and	O
gave	O
infor	O
-	O
mation	O
about	O
the	O
progression	O
of	O
the	O
disease	O
.	O

On	O
the	O
basis	O
of	O
this	O
information	O
,	O
our	O
study	O
was	O
aimed	O
at	O
finding	O
out	O
if	O
p53	O
expression	O
in	O
squamous	O
cell	O
carcinomas	O
correlated	O
with	O
the	O
HPV	O
status	O
.	O

The	O
results	O
show	O
a	O
certain	O
correlation	O
between	O
the	O
p53	O
-	O
positive	O
expression	O
and	O
HPV	O
-	O
negative	O
status	O
of	O
tumors	O
.	O

It	O
can	O
be	O
caused	O
by	O
smoking	O
.	O

More	O
than	O
a	O
half	O
of	O
HPV	O
-	O
negative	O
/	O
p53	O
-	O
positive	O
patients	O
smoked	O
in	O
the	O
past	O
and	O
smoking	O
of	O
tobacco	O
increases	O
the	O
frequency	O
of	O
p53	O
mutations	O
(	O
18	O
)	O
.	O

The	O
p53	O
mutant	O
is	O
usually	O
more	O
stable	O
but	O
can	O
be	O
more	O
expressed	O
in	O
neoplastic	O
tissue	O
than	O
in	O
normal	O
tissue	O
.	O

The	O
RAS	O
family	O
oncogenes	O
(	O
Hras	O
,	O
Kras	O
a	O
Nras	O
)	O
are	O
strongly	O
involved	O
in	O
cancer	O
pathogenesis	O
and	O
thus	O
highly	O
relevant	O
.	O

In	O
case	O
of	O
colorectal	O
cancer	O
,	O
it	O
was	O
proved	O
that	O
patients	O
with	O
these	O
genes’	O
mutations	O
do	O
not	O
respond	O
to	O
AntiEGFR	O
therapy	O
,	O
i	O
.	O
e	O
.	O
to	O
cetuximab	O
.	O

Patients	O
with	O
HNSCC	O
can	O
benefit	O
from	O
antiEGFR	O
therapy	O
(	O
ce	O
-	O
tuximab	O
)	O
but	O
the	O
treatment	O
predictor	O
(	O
in	O
contrast	O
to	O
CRC	O
-	O
colorectal	O
cancer	O
)	O
is	O
not	O
defined	O
yet	O
.	O

This	O
study	O
aimed	O
to	O
assess	O
the	O
incidence	O
of	O
mutation	O
as	O
a	O
possible	O
predictor	O
of	O
cetuximab	O
treatment	O
in	O
HN	O
-	O
SCC	O
(	O
as	O
in	O
CRC	O
)	O
and	O
evaluate	O
risk	O
factors	O
such	O
as	O
age	O
,	O
gender	O
,	O

location	O
and	O
smoking	O
.	O

Kit	O
et	O
al	O
studied	O
the	O
frequency	O
of	O
codon	O
12	O
mutations	O
and	O
proved	O
that	O
gender	O
does	O
not	O
play	O
any	O
role	O
(	O
19	O
)	O

In	O
the	O
latter	O
study	O
,	O
2	O
/	O
11	O
females	O
had	O
codon	O
12	O
mutations	O
(	O
18	O
.	O
2	O
%	O
)	O
and	O
9	O
/	O
11	O
females	O
were	O
WT	O
(	O
81	O
.	O
8	O
%	O
)	O
.	O

Both	O
women	O
with	O
codon	O
12	O
mutations	O
were	O
older	O
than	O
52	O
.	O

As	O
many	O
as	O
3	O
/	O
44	O
males	O
in	O
this	O
study	O
had	O
codon	O
12	O
mutations	O
(	O
6	O
.	O
82	O
%	O
)	O
and	O
41	O
/	O
44	O
males	O
were	O
WT	O
(	O
93	O
.	O
18	O
%	O
)	O
.	O

All	O
three	O
men	O
were	O
older	O
than	O
59	O
.	O

Patients	O
with	O
Kras	O
mutations	O
were	O
older	O
than	O
52	O
(	O
median	O
62	O
.	O
8	O
years	O
)	O
which	O
corresponds	O
with	O
the	O
study	O
conducted	O
by	O
Baskin	O
et	O
al	O
where	O
the	O
same	O
median	O
was	O
stated	O
(	O
62	O
.	O
2	O
years	O
)	O
(	O
20	O
)	O
.	O

One	O
of	O
the	O
reasons	O
why	O
tumors	O
affect	O
mostly	O
older	O
patients	O
can	O
lie	O
in	O
gradual	O
cumulation	O
of	O
mutations	O
.	O

In	O
the	O
hereditary	O
form	O
of	O
tumor	O
disease	O
,	O
just	O
one	O
mutation	O
of	O
a	O
somatic	O
cell	O
is	O
sufficient	O
to	O
elimi	O
-	O
nate	O
the	O
gene	O
.	O

Whereas	O
in	O
a	O
sporadic	O
form	O
,	O
there	O
is	O
a	O
multilevel	O
process	O
followed	O
by	O
cumulation	O
of	O
mutations	O
in	O
a	O
newly	O
created	O
cell	O
clone	O
.	O

Mammas	O
et	O
al	O
demonstrated	O
that	O
Kras	O
(	O
and	O
also	O
Nras	O
)	O
mu	O
-	O
tations	O
occur	O
more	O
in	O
HPV	O
-	O
positive	O
patients	O
,	O
in	O
comparison	O
to	O
HPV	O
-	O
negative	O
patients	O
.	O

In	O
our	O
study	O
,	O
we	O
detected	O
4	O
HPV	O
-	O
positive	O
cases	O
and	O
3	O
HPV	O
-	O
negative	O
cases	O
,	O
which	O
corresponds	O
to	O
the	O
results	O
of	O
Mammas	O
et	O
al	O
(	O
21	O
)	O
.	O

Tumors	O
with	O
mutated	O
codons	O
of	O
the	O
Kras	O
gene	O
were	O
most	O
fre	O
-	O
quently	O
found	O
in	O
the	O
oropharynx	O
.	O

In	O
the	O
study	O
conducted	O
by	O
Küçük	O
et	O
al	O
,	O
the	O
most	O
tumors	O
with	O
mutated	O
Kras	O
gene	O
were	O
also	O
found	O
in	O
the	O
oropharyngeal	O
area	O
but	O
no	O
close	O
association	O
between	O
tumor	O
location	O
and	O
Kras	O
mutation	O
was	O
observed	O
(	O
22	O
)	O
.	O

The	O
literature	O
describing	O
Kras	O
mutations	O
in	O
condon	O
146	O
in	O
HN	O
-	O
SCC	O
is	O
insufficient	O
.	O

In	O
our	O
study	O
,	O
we	O
detected	O
2	O
mutations	O
(	O
3	O
.	O
63	O
%	O
)	O
in	O
codon	O
146	O
,	O
which	O
correlates	O
with	O
the	O
results	O
in	O
the	O
study	O
Loupa	O
-	O

Stanek	O
L	O
et	O
al	O
.	O

Molecular	O
and	O
IHC	B-HPV_Lab_Technique
analysis	O
of	O
head	O
and	O
neck	O
carcinomas	O
associated	O
with	O
HPV	O
infection	O

kis	O
et	O
al	O
.	O

Current	O
studies	O
are	O
focused	O
mainly	O
on	O
the	O
frequency	O
of	O
mutations	O
and	O
their	O
function	O
as	O
treatment	O
predictors	O
(	O
23	O
)	O
.	O

Our	O
study	O
found	O
a	O
strong	O
correlation	O
between	O
codon	O
146	O
mu	O
-	O
tation	O
and	O
HPV	O
infection	O
but	O
this	O
fact	O
does	O
not	O
mean	O
a	O
causal	O
re	O
-	O
lation	O
between	O
variables	O
while	O
the	O
low	O
amount	O
of	O
input	O
data	O
must	O
be	O
also	O
taken	O
into	O
consideration	O
.	O

Clinical	O
studies	O
devoted	O
to	O
the	O
Ras	O
gene	O
mutations	O
in	O
HNSCC	O
as	O
possible	O
predictors	O
of	O
cetuximab	O
treatment	O
are	O
focused	O
mainly	O
on	O
Kras	O
mutations	O
.	O

For	O
that	O
reason	O
,	O
the	O
data	O
for	O
comparing	O
Nras	O
mutations	O
with	O
the	O
risk	O
factors	O
in	O
HNSCC	O
are	O
not	O
sufficient	O
.	O

This	O
study	O
detected	O
Nras	O
mutation	O
in	O
exon	O
2	O
in	O
2	O
/	O
54	O
patients	O
(	O
3	O
.	O
7	O
%	O
)	O
,	O
so	O
the	O
frequency	O
was	O
very	O
low	O
.	O

A	O
similar	O
frequency	O
was	O
detected	O
in	O
the	O
study	O
conducted	O
by	O
Irahara	O
et	O
al	O
where	O
mutations	O
of	O
the	O
Nras	O
gene	O
were	O
found	O
in	O
5	O
/	O
225	O
patients	O
with	O
CRC	O
(	O
24	O
)	O
.	O

The	O
study	O
of	O
Irahara	O
et	O
al	O
confirmed	O
that	O
Nras	O
mutations	O
are	O
less	O
frequent	O
than	O
Kras	O
mutations	O
.	O

Only	O
one	O
HPV	O
-	O
positive	O
patient	O
had	O
a	O
Nras	O
mutation	O
in	O
exon	O

2	O
.	O

Statistically	O
,	O
no	O
correlation	O
between	O
Kras	O
and	O
Nras	O
mutations	O
and	O
HPV	O
infection	O
was	O
found	O
.	O

That	O
supports	O
the	O
hypothesis	O
that	O
HPV	O
-	O
induced	O
tumors	O
have	O
a	O
different	O
molecular	O
mechanism	O
of	O
development	O
and	O
do	O
not	O
have	O
so	O
many	O
point	O
mutations	O
(	O
including	O
Kras	O
and	O
Nras	O
)	O
as	O
tumors	O
developed	O
spontaneously	O
.	O

This	O
study	O
detected	O
one	O
Braf	O
mutation	O
which	O
marginally	O
cor	O
-	O
related	O
with	O
laryngeal	O
location	O
of	O
a	O
tumor	O
which	O
was	O
removed	O
with	O
resection	O
boundaries	O
.	O

Due	O
to	O
the	O
single	O
finding	O
of	O
positive	O
Braf	O
mutation	O
,	O
this	O
result	O
(	O
as	O
well	O
as	O
the	O
correlation	O
with	O
gender	O
and	O
age	O
)	O
cannot	O
be	O
regarded	O
as	O
relevant	O
.	O

V600	O
is	O
described	O
as	O
the	O
most	O
frequent	O
mutation	O
of	O
the	O
Braf	O
gene	O
.	O

This	O
mutation	O
is	O
also	O
detected	O
in	O
CRC	O
.	O

Our	O
study	O
found	O
c	O
.	O
1808	O
G	O
>	O
A	O
mutation	O
,	O
protein	O
603	O
Arg	O
>	O
Gln	O
.	O

This	O
mutation	O
has	O
not	O
been	O
described	O
yet	O
,	O
so	O
its	O
importance	O
as	O
a	O
predictive	O
and	O
/	O
or	O
prognostic	O
factor	O
cannot	O
be	O
defined	O
.	O

The	O
aim	O
of	O
this	O
work	O
was	O
to	O
find	O
HVP	O
infection	O
in	O
HNSCC	O
and	O
its	O
potential	O
correlation	O
with	O
P16INK4A	O
and	O
p53	O
as	O
a	O
possible	O
diagnostic	O
biomarker	O
.	O

This	O
work	O
confirmed	O
that	O
IHC	O
can	O
be	O
used	O
as	O
a	O
reliable	O
diag	O
-	O
nostic	O
biomarker	O
for	O
HPV	O
-	O
positive	O
HNSCC	O
.	O

IHC	O
also	O
detected	O
a	O
correlation	O
between	O
p53	O
and	O
HPV	O
-	O
negative	O
HNSCC	O
.	O

Therefore	O
,	O
p53	O
IHC	O
can	O
be	O
used	O
as	O
a	O
possible	O
prognostic	O
biomarker	O
of	O
HPV	O
-	O
negative	O
HNSCC	O
.	O

This	O
work	O
also	O
studied	O
the	O
incidence	O
of	O
Ras	O
and	O
Braf	O
muta	O
-	O
tions	O
in	O
HNSCC	O
and	O
simultaneous	O
influence	O
of	O
risk	O
factors	O
.	O

The	O
study	O
found	O
an	O
association	O
of	O
oropharyngeal	O
tumor	O
location	O
and	O
Kras	O
mutations	O
and	O
a	O
correlation	O
between	O
Kras	O
mutations	O
and	O
smoking	O
.	O

HPV	O
infection	O
correlated	O
with	O
Kras	O
mutations	O
in	O
codon	O
146	O
but	O
the	O
data	O
are	O
not	O
statistically	O
significant	O
because	O
the	O
group	O
of	O
patients	O
was	O
quite	O
small	O
.	O

The	O
found	O
Braf	O
mutation	O
has	O
not	O
been	O
described	O
yet	O
,	O
so	O
we	O
cannot	O
evaluate	O
its	O
predictive	O
and	O
prognostic	O
importance	O
.	O

The	O
documented	O
data	O
show	O
the	O
necessity	O
of	O
classifying	O
the	O
molecular	O
subtypes	O
of	O
HNSCC	O
and	O
applying	O
individual	O
therapeutic	O
approach	O
on	O
the	O
basis	O
of	O
molecular	O
testing	O
.	O

References	O

Garnaes	O
E	O
,	O
Kiss	O
K	O
,	O
Andersen	O
L	O
,	O
Therkildsen	O
MH	O
,	O
Franzmann	O
MB	O
et	O
al	O
.	O

A	O
high	O
and	O
increasing	O
HPV	O
prevalence	B-Incidence_or_Prevalence
in	O
tonsillar	O
cancers	O
in	O
East	B-Study_Location
-	I-Study_Location
ern	I-Study_Location
Denmark	I-Study_Location
,	O
2000‒2010	O
:	O
the	O
largest	O
registry	O
-	O
based	O
study	O
to	O
date	O
.	O

Int	O
J	O
Cancer	O
2015	O
;	O
136	O
(	O
9	O
)	O
:	O
2196‒203	O
.	O

Polz	O
-	O
gruszka	O
D	O
,	O
Stec	O
A	O
,	O
Dworzański	O
J	O
,	O
Polz	O
-	O
dacewicz	O
M	O
.	O

EBV	O
,	O
HSV	O
,	O
CMV	O
and	O
HPV	O
in	O
laryngeal	O
and	O
oropharyngeal	O
carcinoma	O
in	O
polish	O
pa	O
-	O
tients	O
.	O

Anticancer	O
Res	O
2015	O
;	O
1662	O
(	O
35	O
)	O
:	O
1657–1661	O
.	O

Goldenberg	O
D	O
,	O
Benoit	O
NE	O
,	O
Begum	O
S	O
,	O
Westra	O
WH	O
,	O
Cohen	O
Y	O
,	O
Koch	O
WM	O
,	O
Califano	O
JA	O
.	O

Epstein	O
-	O
Barr	O
virus	O
in	O
head	O
and	O
neck	O
cancer	O
assessed	O
by	O
quantitative	B-HPV_Lab_Technique
polymerase	I-HPV_Lab_Technique
chain	I-HPV_Lab_Technique
reaction	I-HPV_Lab_Technique
.	O

Laryngoscope	O
2004	O
;	O
114	O
(	O
6	O
)	O
:	O
1027–1031	O
.	O

Focchi	O
GRA	O
,	O
Silva	O
IDCG	O
,	O
Nogueira	O
-	O
de	O
-	O
souza	O
NC	O
,	O
Dobo	O
C	O
,	O
Os	O
-	O
hima	O
CT	O
,	O
Stavale	O
N	O
.	O

Immunohistochemical	O
expression	O
of	O
p16	O
(	O
INK4A	O
)	O
in	O
normal	O
uterine	O
cervix	O
,	O
nonneoplastic	O
epithelial	O
lesions	O
,	O
and	O
low	O
-	O
grade	O
squamous	O
intraepithelial	O
lesions	O
.	O

J	O
Low	O
Genit	O
Tract	O
Dis	O
2007	O
;	O
11	O
(	O
2	O
)	O
:	O
98–104	O
.	O

Werness	O
BA	O
,	O
Levine	O
AJ	O
,	O
Howley	O
PM	O
.	O

Association	O
of	O
human	O
pap	O
-	O
illomavirus	O
types	O
16	O
and	O
18	O
E6	O
proteins	O
with	O
p53	O
.	O

Science	O
1990	O
;	O
248	O
(	O
4951	O
)	O
:	O
76	O
LP‒79	O
.	O

Garnett	O
T	O
,	O
Filippova	O
M	O
,	O
Duerksen	O
-	O
Hughes	O
P	O
.	O

Accelerated	O
degradation	O
of	O
FADD	O
and	O
procaspase	O
8	O
in	O
cells	O
expressing	O
human	O
papilloma	O
virus	O
16	O
E6	O
impairs	O
TRAIL	O
-	O
mediated	O
apoptosis	O
.	O

Cell	O
Death	O
Differentiation	O
2007	O
;	O
13	O
(	O
11	O
)	O
:	O
1915–1926	O
.	O

Sano	O
T	O
,	O
Oyama	O
T	O
,	O
Kashiwabara	O
K	O
,	O
The	O
TF	O
,	O
Sano	O
T	O
,	O
Oyama	O
T	O
,	O
Shroy	O
-	O
er	O
AL	O
.	O

Expression	O
status	O
of	O
p16	O
protein	O
is	O
associated	O
with	O
human	O
papillo	O
-	O
mavirus	O
oncogenic	O
potential	O
in	O
cervical	O
and	O
genital	O
lesions	O
.	O

Amer	O
J	O
Pathol	O
2004	O
;	O
153	O
(	O
6	O
)	O
:	O
1741–1748	O
.	O

Mirza	O
A	O
,	O
McGuirk	O
M	O
,	O
Hockenberry	O
TN	O
,	O
Wu	O
Q	O
,	O
Ashar	O
H	O
,	O
Black	O
S	O
,	O
Liu	O
S	O
.	O

Human	O
survivin	O
is	O
negatively	O
regulated	O
by	O
wild	O
-	O
type	O
p53	O
and	O
par	O
-	O
ticipates	O
in	O
p53	O
-	O
dependent	O
apoptotic	O
pathway	O
.	O

Oncogene	O
2002	O
;	O
21	O
(	O
17	O
)	O
:	O
2613–2622	O
.	O

Ang	O
KKP	O
,	O
Harris	O
J	O
,	O
Wheeler	O
R	O
,	O
Weber	O
R	O
,	O
Rosenthal	O
DI	O
,	O
Nguyen	O
-	O
tân	O
PF	O
,	O
Maura	O
LP	O
.	O

Human	O
papillomavirus	O
and	O
survival	O
of	O
patients	O
with	O
oropharyngeal	O
cancer	O
.	O

New	O
Engl	O
J	O
Med	O
2011	O
;	O
363	O
(	O
1	O
)	O
:	O
24–35	O
.	O

Psyrri	O
A	O
,	O
Rampias	O
T	O
,	O
Vermorken	O
JB	O
.	O

The	O
current	O
and	O
future	O
impact	O
of	O
human	O
papillomavirus	O
on	O
treatment	O
of	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
head	O
and	O
neck	O
.	O

Ann	O
Oncol	O
2014	O
;	O
25	O
(	O
11	O
)	O
:	O
2101–2115	O
.	O

De	O
Vuyst	O
H	O
,	O
Clifford	O
G	O
,	O
Li	O
N	O
,	O
Franceschi	O
S	O
.	O

HPV	O
infection	O
in	O
Eu	O
-	O
rope	O
.	O

Eur	O
J	O
Cancer	O
2009	O
;	O
45	O
(	O
15	O
)	O
:	O
2632–2639	O
.	O

Medsker	O
B	O
,	O
Forno	O
E	O
,	O
Simhan	O
H	O
,	O
Juan	O
C	O
,	O
Sciences	O
R	O
.	O

Human	O
papil	O
-	O
lomavirus	O
genotype	O
and	O
oropharynx	O
cancer	O
survival	O
in	O
the	O
United	O
States	O
.	O

Eur	O
J	O
Cancer	O
2016	O
;	O
70	O
(	O
12	O
)	O
:	O
773–779	O
.	O

Faust	O
H	O
,	O
Alwan	O
EE	O
,	O
Roslin	O
A	O
,	O
Wennerberg	O
J	O
,	O
Forslund	O
O	O
.	O

Preva	O
-	O
lence	O
of	O
human	O
papillomavirus	O
types	O
,	O
viral	O
load	O
and	O
physical	O
status	O
of	O
HPV16	O
in	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
from	O
the	O
South	O
Swedish	O
Health	O
Care	O
Region	O
.	O

J	O
Gen	O
Virol	O
2016	O
;	O
97	O
(	O
11	O
)	O
:	O
2949–2956	O
.	O

Kreimer	O
AR	O
,	O
Clifford	O
GM	O
,	O
Boyle	O
P	O
,	O
Kreimer	O
AR	O
,	O
Clifford	O
GM	O
,	O
Boyle	O
P	O
,	O
Franceschi	O
S	O
.	O

Human	O
papillomavirus	O
types	O
in	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinomas	O
worldwide	O
.	O

Cancer	O
Epidemiol	O
Biomarkers	O
Prev	O
2005	O
;	O
14	O
(	O
2	O
)	O
:	O
467–475	O
.	O

Wittekindt	O
C	O
,	O
Gültekin	O
E	O
,	O
Weissenborn	O
SJ	O
,	O
Pfister	O
HJ	O
,	O
Jens	O
P	O
.	O

Ex	O
-	O
pression	O
of	O
p	O
1	O
6	O
Protein	O
Is	O
Associated	O
with	O
Human	O
Papillomavirus	O
Status	O
in	O
Tonsillar	O
Carcinomas	O
and	O
Has	O
2005	O
;	O
62	O
:	O
72–80	O
.	O

Bratisl	O
Med	O
J	O
2019	O
;	O
120	O
(	O
11	O
)	O

832	O
–	O
838	O

Nigro	O
JM	O
,	O
Baker	O
SJ	O
,	O
Preisinger	O
C	O
,	O
Jessup	O
JM	O
,	O
Hostetter	O
R	O
,	O
Cleary	O
K	O
,	O
Devilee	O
P	O
.	O

Mutations	O
in	O
the	O
p53	O
gene	O
occur	O
in	O
diverse	O
human	O
tumour	O
types	O
.	O

Nature	O
1989	O
;	O
342	O
(	O
6250	O
)	O
:	O
705–708	O
.	O

Nadal	O
A	O
,	O
Campo	O
E	O
,	O
Pinto	O
J	O
,	O
Mallofré	O
C	O
,	O
Palacín	O
A	O
,	O
Arias	O
C	O
,	O
Carde	O
-	O
sa	O
A	O
.	O

p53	O
expression	O
in	O
normal	O
,	O
dysplastic	O
,	O
and	O
neoplastic	O
laryngeal	O
epi	O
-	O
thelium	O
.	O

Absence	O
of	O
a	O
correlation	O
with	O
prognostic	O
factors	O
.	O

J	O
Pathol	O
1995	O
;	O
175	O
(	O
2	O
)	O
:	O
181–188	O
.	O

Halvorsen	O
A	O
,	O
Silwal	O
-	O
Pandit	O
L	O
,	O
Meza	O
-	O
Zepeda	O
L	O
,	O
Vodak	O
D	O
,	O
Vu	O
P	O
,	O
Sagerup	O
C	O
,	O
Helland	O
A	O
.	O

TP53	O
mutation	O
spectrum	O
in	O
smokers	O
and	O
never	O
smoking	O
lung	O
cancer	O
patients	O
.	O

Front	O
Genet	O
2016	O
;	O
(	O
5	O
)	O
:	O
1–10	O
.	O

Kit	O
O	O
,	O
Vodolazhskiy	O
D	O
,	O
Gevorkyan	O
Y	O
,	O
Soldatkina	O
N	O
.	O

KRAS	O
gene	O
mutations	O
and	O
gender	O
differences	O
in	O
colorectal	O
cancer	O
.	O

Internat	O
J	O
Biomed	O
2015	O
;	O
5	O
(	O
1	O
)	O
:	O
11–15	O
.	O

Baskin	O
Y	O
,	O
Dagdeviren	O
YK	O
,	O
Calibasi	O
G	O
,	O
Canda	O
AE	O
,	O
Sarioglu	O
S	O
,	O
El	O
-	O
lidokuz	O
H	O
,	O
Oztop	O
I	O
.	O

KRAS	O
mutation	O
profile	O
differences	O
between	O
recto	O
-	O
sigmoid	O
localized	O
adenocarcinomas	O
and	O
colon	O
adenocarcinomas	O
.	O

J	O
Gas	O
-	O
trointest	O
Oncol	O
2014	O
;	O
5	O
(	O
4	O
)	O
:	O
265–269	O
.	O

Mammas	O
IN	O
,	O
Zafiropoulos	O
A	O
,	O
Sifakis	O
S	O
,	O
Sourvinos	O
G	O
,	O
Spandidos	O
DA	O
.	O

Human	O
papillomavirus	O
(	O
HPV	O
)	O
typing	O
in	O
relation	O
to	O
ras	O
oncogene	O
mRNA	O
expression	O
in	O
HPV	O
-	O
associated	O
human	O
squamous	O
cervical	O
neoplasia	O
.	O

Internat	O
J	O
Biol	O
Markers	O
ľééť	O
;	O
20	O
(	O
4	O
)	O
:	O
257–263	O
.	O

Küçük	O
Ü	O
,	O
Bayol	O
Ü	O
,	O
Usturalı	O
Keskin	O
E	O
,	O
Pala	O
EE	O
,	O
Çukurova	O
İ	O
,	O
Ço	O
-	O
lak	O
MA	O
,	O
Koç	O
A	O
.	O

Investigating	O
KRAS	O
/	O
BRAF	O
mutation	O
in	O
oropharyngeal	O
squamous	O
cell	O
carcinomas	O
:	O
a	O
preliminary	O
study	O
.	O

J	O
Ear	O
,	O
Nose	O
,	O
Throat	O
2016	O
;	O
26	O
(	O
5	O
)	O
:	O
2–4	O
.	O

Loupakis	O
F	O
,	O
Ruzzo	O
A	O
,	O
Cremolini	O
C	O
,	O
Vincenzi	O
B	O
,	O
Salvatore	O
L	O
,	O
Santini	O
D	O
et	O
al	O
.	O

KRAS	O
codon	O
61	O
,	O
146	O
and	O
BRAF	O
mutations	O
predict	O
resistance	O
to	O
cetuximab	O
plus	O
irinotecan	O
in	O
KRAS	O
codon	O
12	O
and	O
13	O
wild	O
-	O
type	O
metastatic	O
colorectal	O
cancer	O
.	O

Brit	O
J	O
Cancer	O
2009	O
;	O
101	O
(	O
4	O
)	O
:	O
715–721	O
.	O

Irahara	O
N	O
,	O
Baba	O
Y	O
,	O
Nosho	O
K	O
,	O
Shima	O
K	O
,	O
Yan	O
L	O
,	O
Dias	O
-	O
Santagata	O
D	O
et	O
al	O
.	O

NRAS	O
mutations	O
are	O
rare	O
in	O
colorectal	O
cancer	O
.	O

Diagn	O
Mol	O
Pathol	O
2010	O
;	O
19	O
(	O
3	O
)	O
:	O
157–163	O
.	O

Received	O
June	O
18	O
,	O
2019	O
.	O

Accepted	O
July	O
6	O
,	O
2019	O
.	O

